Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology,General Medicine
Link
http://link.springer.com/content/pdf/10.1007/s00210-015-1146-x.pdf
Reference23 articles.
1. Brouillette J, Clark RB, Giles WR, Fiset C (2004) Functional properties of K+ currents in adult mouse ventricular myocytes. J Physiol 559:777–798
2. Camm AJ, Lip GYH, Caterina R, Savelieva I, et al (2012) ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Eur Heart J 33:2719–2747
3. Fedorov VV, Sharifov OF, Beloshapko GG, Yushmanova AV, Rosenshtraukh LV (2000) Effects of a new class III antiarrhythmic drug nibentan in a canine model of vagally mediated atrial fibrillation. J Cardiovasc Pharmacol 36:77–89
4. Fedorov VV, Rosenshtraukh LV, Reznik AV, et al (2004) Antiarrhythmic efficacy of a new class III antiarrhythmic drug RG-2. Kardiologiia 44:66–74
5. Finnin M (2010) Vernakalant: a novel agent for the termination of atrial fibrillation. Am J Health Syst Pharm 67:1157–1164
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Characterization of hERG K+ channel inhibition by the new class III antiarrhythmic drug cavutilide;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-01-15
2. The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium Activation;Bulletin of Experimental Biology and Medicine;2023-03
3. PharmaLab: A Tool to Study the Drug Action on the Mouse Ventricular Myocyte;Journal of Physics: Conference Series;2022-04-01
4. Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms;Frontiers in Pharmacology;2020-11-09
5. A New Class III Antiarrhythmic Drug Niferidil Prolongs Action Potentials in Guinea Pig Atrial Myocardium via Inhibition of Rapid Delayed Rectifier;Cardiovascular Drugs and Therapy;2017-11-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3